Cargando…
Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
Viral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable preventative and treatment options, including during global emergencies. Here...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224075/ https://www.ncbi.nlm.nih.gov/pubmed/37242780 http://dx.doi.org/10.3390/pharmaceutics15051538 |
_version_ | 1785050091301634048 |
---|---|
author | Struble, Evi B. Rawson, Jonathan M. O. Stantchev, Tzanko Scott, Dorothy Shapiro, Marjorie A. |
author_facet | Struble, Evi B. Rawson, Jonathan M. O. Stantchev, Tzanko Scott, Dorothy Shapiro, Marjorie A. |
author_sort | Struble, Evi B. |
collection | PubMed |
description | Viral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable preventative and treatment options, including during global emergencies. Here we will discuss polyclonal and monoclonal antiviral antibody therapies, focusing on the unique biochemical and physiological properties that make them well-suited as therapeutic agents. We will describe the methods of antibody characterization and potency assessment throughout development, highlighting similarities and differences between polyclonal and monoclonal products as appropriate. In addition, we will consider the benefits and challenges of antiviral antibodies when used in combination with other antibodies or other types of antiviral therapeutics. Lastly, we will discuss novel approaches to the characterization and development of antiviral antibodies and identify areas that would benefit from additional research. |
format | Online Article Text |
id | pubmed-10224075 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102240752023-05-28 Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies Struble, Evi B. Rawson, Jonathan M. O. Stantchev, Tzanko Scott, Dorothy Shapiro, Marjorie A. Pharmaceutics Review Viral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable preventative and treatment options, including during global emergencies. Here we will discuss polyclonal and monoclonal antiviral antibody therapies, focusing on the unique biochemical and physiological properties that make them well-suited as therapeutic agents. We will describe the methods of antibody characterization and potency assessment throughout development, highlighting similarities and differences between polyclonal and monoclonal products as appropriate. In addition, we will consider the benefits and challenges of antiviral antibodies when used in combination with other antibodies or other types of antiviral therapeutics. Lastly, we will discuss novel approaches to the characterization and development of antiviral antibodies and identify areas that would benefit from additional research. MDPI 2023-05-19 /pmc/articles/PMC10224075/ /pubmed/37242780 http://dx.doi.org/10.3390/pharmaceutics15051538 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Struble, Evi B. Rawson, Jonathan M. O. Stantchev, Tzanko Scott, Dorothy Shapiro, Marjorie A. Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies |
title | Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies |
title_full | Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies |
title_fullStr | Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies |
title_full_unstemmed | Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies |
title_short | Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies |
title_sort | uses and challenges of antiviral polyclonal and monoclonal antibody therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224075/ https://www.ncbi.nlm.nih.gov/pubmed/37242780 http://dx.doi.org/10.3390/pharmaceutics15051538 |
work_keys_str_mv | AT strubleevib usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies AT rawsonjonathanmo usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies AT stantchevtzanko usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies AT scottdorothy usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies AT shapiromarjoriea usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies |